Phase 1 vs. Phase 2 Deal Valuation Comparison

Phase 1 Median Upfront

$90M

Total: $882M

Phase 2 Median Upfront

$258M

Total: $1.6B

Phase Transition Premium

86%

Phase 2 premium over Phase 1

Phase 1 Royalty Range

8.6%-15%

vs Phase 2: 11.8%-19.3%

Model Your Deal

Market Analysis

The Phase 1 to Phase 2 transition represents the most significant value inflection point in pharmaceutical licensing. Phase 2 small molecule deals carry a median total deal value of $1.6B compared to $882M at Phase 1, representing a 86% premium for clinical proof-of-concept data. Upfront payments increase from $90M to $258M.

The risk-adjusted deal structures differ significantly between phases. Phase 1 deals are heavily milestone-weighted with $317M in development milestones, while Phase 2 deals shift toward higher upfronts and commercial milestones. Phase 1 development milestones often include proof-of-concept triggers that Phase 2 deals have already de-risked. Regulatory milestones increase from $277M to $552M.

Royalty rates also reflect the de-risking premium. Phase 1 base royalties range from 8.6% to 15%, while Phase 2 assets command 11.8% to 19.3%. The optimal licensing window for most assets is immediately after Phase 2a proof-of-concept data, when the risk-value trade-off most favors the licensor.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical deal value premium from Phase 1 to Phase 2?

Phase 2 deals command a 86% premium over Phase 1 in total deal value ($1.6B vs $882M). The upfront payment increase is even more pronounced: $258M vs $90M, reflecting the de-risking value of proof-of-concept clinical data.

How do risk-adjusted deal terms differ between Phase 1 and Phase 2?

Phase 1 deals allocate a larger share to development milestones ($317M) relative to upfront payments, reflecting higher clinical risk. Phase 2 deals shift the value split toward upfront ($258M) and commercial milestones, reflecting the reduced probability of clinical failure after proof-of-concept data.

When is the optimal time to out-license a pharmaceutical asset?

The optimal licensing window depends on therapeutic area and modality, but the Phase 2a readout inflection point is generally the most favorable for licensors. At this stage, clinical proof-of-concept has been established, the asset carries a de-risking premium, and the licensee still captures substantial upside from Phase 3 and commercialization. Pre-Phase 2a licensing is appropriate when capital constraints or platform validation needs outweigh the value of additional de-risking.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 1 vs. Phase 2 Deal Valuation Comparison

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Deal Benchmarks

Phase 2 Deal Benchmarks

Phase 3 Deal Benchmarks

Oncology Deal Overview 2026

Ready to Calculate Your Deal Terms?